Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Nassim Djebli"'
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 13, Iss 7, Pp 1238-1251 (2024)
Abstract Adebrelimab, a novel anti‐PD‐L1 antibody, has been approved by the National Medical Products Administration of China as an intravenous infusion for use in combination with carboplatin and etoposide as first‐line treatment for extensive
Externí odkaz:
https://doaj.org/article/7d2626eea34a4ba0b241e66ef4fbc885
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 13, Iss 3, Pp 396-409 (2024)
Abstract Glofitamab is a novel T cell bispecific antibody developed for treatment of relapsed‐refractory diffuse large B cell lymphoma and other non‐Hodgkin's lymphoma indications. By simultaneously binding human CD20‐expressing tumor cells and
Externí odkaz:
https://doaj.org/article/7f592a5758c04aa3a48cc531488fe90e
Autor:
Georgina Meneses-Lorente, Elena Guerini, Francois Mercier, Neil Parrott, Karey Kowalski, Edna Chow-Maneval, Vincent Buchheit, Guillaume Bergthold, Elizabeth Fox, Alex Phipps, Nassim Djebli
Publikováno v:
Cancer Chemotherapy and Pharmacology. 91:239-246
Purpose Entrectinib is a central nervous system-active potent inhibitor of tropomyosin receptor kinase (TRK), with anti-tumor activity against neurotrophic NTRK gene fusion-positive tumors. This study investigates the pharmacokinetics of entrectinib
Autor:
Nassim Djebli, Pierre-Olivier Tremblay, Vincent Buchheit, Mario González-Sales, Guillaume Bonnefois, Georgina Meneses-Lorente, Francois Mercier, Nicolas Frey
Publikováno v:
Cancer Chemotherapy and Pharmacology. 88:997-1007
Entrectinib (ROZLYTREK®) is a CNS-active, potent, and selective inhibitor of ROS1, TRK A/B/C, and ALK kinase activity. It was recently approved for the treatment of ROS1-positive non-small cell lung cancer and NTRK gene fusion-positive solid tumors.
Autor:
Li Yu, Elena Guerini, Georgina Meneses-Lorente, Alex Phipps, Vincent Buchheit, Nassim Djebli, Francois Mercier, Yumi Cleary, Stephen Fowler, Nicolas Frey, Neil Parrott
Publikováno v:
European Journal of Drug Metabolism and Pharmacokinetics. 46:779-791
Entrectinib is a selective inhibitor of ROS1/TRK/ALK kinases, recently approved for oncology indications. Entrectinib is predominantly cleared by cytochrome P450 (CYP) 3A4, and modulation of CYP3A enzyme activity profoundly alters the pharmacokinetic
Publikováno v:
European journal of drug metabolism and pharmacokinetics. 47(6)
Alirocumab is a cholesterol-lowering monoclonal antibody targeting proprotein convertase subtilisin kexin type 9 (PCSK9) indicated in the prevention of cardiovascular risk and exhibiting target-mediated drug disposition (TMDD). The aim of this work w
Autor:
Darren Bentley, Nassim Djebli, Andreas Brink, Edna Chow-Maneval, Elena Guerini, Karey Kowalski, Vincent Buchheit, Francois Mercier, Georgina Meneses-Lorente, Alex Phipps, Li Yu
Publikováno v:
Investigational New Drugs
SummaryBackground: Entrectinib is an oral, CNS-active, potent inhibitor of tyrosine receptor kinases A/B/C, tyrosine kinase ROS proto-oncogene 1, and anaplastic lymphoma kinase approved for use in patients with solid tumors. We describe 3 clinical st
Publikováno v:
European journal of drug metabolism and pharmacokinetics
European journal of drug metabolism and pharmacokinetics, Springer, In press, ⟨10.1007/s13318-021-00709-w⟩
European journal of drug metabolism and pharmacokinetics, 2021, 46 (5), pp.695-705. ⟨10.1007/s13318-021-00709-w⟩
European journal of drug metabolism and pharmacokinetics, Springer, In press, ⟨10.1007/s13318-021-00709-w⟩
European journal of drug metabolism and pharmacokinetics, 2021, 46 (5), pp.695-705. ⟨10.1007/s13318-021-00709-w⟩
International audience; Background and Objectives: Meropenem is frequently used for the treatment of severe bacterial infections in critically ill patients. Because critically ill patients are more prone to pharmacokinetic variability than other pati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f362f1e15787a431a9a73e4dd81c57ee
https://hal.archives-ouvertes.fr/hal-03326864
https://hal.archives-ouvertes.fr/hal-03326864
Autor:
Neil, Parrott, Cordula, Stillhart, Marc, Lindenberg, Bjoern, Wagner, Karey, Kowalski, Elena, Guerini, Nassim, Djebli, Georgina, Meneses-Lorente
Publikováno v:
The AAPS Journal. 22
Entrectinib is a potent and selective tyrosine kinase inhibitor (TKI) of TRKA/B/C, ROS1, and ALK with both systemic and CNS activities, which has recently received FDA approval for ROS1 fusion-positive non-small cell lung cancer and NTRK fusion-posit
Autor:
Aurélie Brunet, Xavier Nicolas, Jean-Marie Martinez, Clémence Rauch, David Fabre, Fabrice Hurbin, Nassim Djebli
Publikováno v:
Clinical Pharmacokinetics
Background Alirocumab, a human monoclonal antibody against proprotein convertase subtilisin/kexin type 9 (PCSK9), significantly lowers low-density lipoprotein cholesterol levels. Objective This analysis aimed to develop and qualify a population pharm